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CASE REPORT
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Abstract : The prognosis of relapsed or refractory lymphoma with central nervous system (CNS) involvement 
remains poor because of the lack of anticancer drugs with sufficient CNS penetration. [Case 1] A 65-year-old 
man was diagnosed with Stage IV mantle cell lymphoma. After two courses of chemotherapy and autologous 
hematopoietic stem cell (HSC) collection, urinary retention with fever developed. Cerebrospinal fluid analysis 
revealed leptomeningeal involvement, which was refractory to high-dose methotrexate therapy. Autologous pe-
ripheral blood stem cell transplantation (ASCT) was performed, followed by intravenous busulfan (ivBU), cyclo-
phosphamide, and etoposide ; thereafter, no relapse has been detected for over six years. [Case 2] A 40-year-old 
woman with right lower hemiplegia was diagnosed with primary CNS lymphoma. Although four courses of high-
dose methotrexate therapy were administered, the cerebral tumor increased in size. HSCs were collected after 
methotrexate therapy, and ASCT was performed in addition to conditioning using ivBU, cyclophosphamide, and 
etoposide, followed by whole-brain and local boost irradiation. She achieved complete remission, but relapsed 
two years after ASCT. High-dose ivBU-containing conditioning regimens with ASCT may be useful for refractory 
B-cell lymphoma with CNS involvement. J. Med. Invest. 68 : 196-201, February, 2021
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INTRODUCTION
 
Involvement of the central nervous system by malignant 
lymphoma is a serious event for lymphoma patients. High-dose 
methotrexate (MTX)-based combination chemotherapy is com-
monly performed for patients with primary or secondary CNS 
invasion of malignant lymphoma in Japan. However, as they 
have a poor prognosis, new therapeutic strategies are needed. 
We report two MTX resistant B-cell lymphoma patients with 
central nervous system invasion in whom autologous peripheral 
blood stem cell transplantation (ASCT) followed by intravenous 
busulfan (ivBU)-based conditioning chemotherapy was effective. 
CASE REPORT
[Case 1] A 65-year-old man with a past history of glaucoma 
perceived right inguinal lymphadenopathy in X-6. Needle biopsy 
demonstrated the proliferation of abnormal lymphocytes positive 
for CD5, CD20, and cyclin D1, and negative for CD3 and CD10, 
and he was diagnosed with mantle cell lymphoma in January 
X. 18F-fluorodeoxyglucose-positron emission tomography / com-
puted tomography (PET / CT) and bone marrow examination 
revealed the involvement of paraaortic, axillary, and right ingui-
nal lymph nodes and bone marrow, and the disease was Stage 
IV based on the Ann-Arbor classification. He achieved a partial 
response after we administered two courses of rituximab plus 
fractionated cyclophosphamide, vincristine, doxorubicin, and 
dexamethasone alternating with high-dose methotrexate-cytar-
abine (R-hyper-CVAD / MTX-AraC), and collected his peripheral 
blood stem cells during the period of leucocyte recovery. High 
fever with bladder and rectal disturbance developed in June X. 
Cerebrospinal fluid (CSF) revealed lymphocytosis (163 / μL) (cy-
tology class IV) with increased protein (129 mg / dL). High signal 
in the spinal cord at the level of Th12 was noted on T2-weighted 
MRI, confirming leptomeningeal involvement of mantle cell 
lymphoma. Systemic MTX chemotherapy with an increased 
dose of 3.5 g / m2 with repetitive intrathecal chemotherapy did 
not remove the lymphoma cells in the CSF. We administered 
ivBU (3.2 mg / kg / day ; days -7, -6, -5, and -4), cyclophosphamide 
(CY) (40 mg / kg / day ; days -3 and -2), and etoposide (VP-16) 
(200 mg / m2 ; days -5 and -4) as conditioning chemotherapy after 
receiving written informed consent, followed by ASCT with 
CD34-positive cells at 6.79 × 106 / kg for residual lymphoma in the 
CNS (Figure 1). He developed no serious adverse events except 
for neutropenia and thrombocytopenia, with grade 4 oral muco-
sitis and grade 3 febrile neutropenia. He achieved engraftment 
on day 10 for neutrophils, day 21 for reticulocytes, and day 21 for 
platelets. No relapse has been detected for over 7 years.
[Case 2] A 40-year-old woman developed incomplete right leg 
muscle weakness with numbness in July Y-1. Brain CT revealed 
a tumor of 2 cm in diameter at the left cingulate convolution with 
surrounding widespread edema (Figure 2). Stereotactic biopsy of 
the brain tumor in September Y-1 demonstrated diffuse prolif-
eration of atypical large lymphocytes positive for bcl-2, MUM-1, 
and CD20, and negative for CD3, CD5, and CD10 on immunos-
taining. We diagnosed her with diffuse large B-cell lymphoma 
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and performed intravenous high-dose MTX and Ara-C combina-
tion chemotherapy with rituximab, and intrathecal chemother-
apy using MTX and Ara-C with dexamethasone. She achieved 
a partial response after three courses of chemotherapy, but the 
disease progressed with right leg paralysis. Autologous stem 
cell collection was performed after receiving written informed 
consent after the fifth course of R-MTX / Ara-C therapy, and 
high-dose chemotherapy followed by ASCT with CD34-positive 
cells at 4.93×106 / kg was administered. The conditioning regi-
men was ivBU (3.2 mg / kg / day ; days -7, -6, -5, and -4), CY (60 
mg / day ; days -3 and -2), and VP-16 (400 mg / m2 ; day -4) (Figure 
3). She developed no serious adverse events except for neutrope-
nia and thrombocytopenia with grade 4 oral mucositis and grade 
3 febrile neutropenia. She achieved engraftment on day 10 for 
neutrophils and day 20 for platelets. After engraftment, we per-
formed whole-brain radiotherapy (36 Gy / 18 fractions) followed 
by local boost irradiation (10 Gy / 5 fractions). Two years and two 
months after ASCT, she developed a cerebeller lesion, which was 
suspected to be relapsed lymphoma, and died.
Figure 1.　Clinical course of case 1
A 65-year-old man with Stage IV mantle cell lymphoma patient was treated using R-hyperCVAD / MTX + Ara-C chemotherapy. After 
the third course of R-hyper-CVAD, fever with bladder and rectal disorder developed. Increased lymphocytosis with cytology class IV 
and abnormal Th12 signal on T2-weighted MRI revealed leptomeningeal involvement of malignant lymphoma. He was resistant to 
MTX ; therefore, we administered ivBU, cyclophosphamide, and etoposide (BUCYE) conditioning chemotherapy followed by ASCT. He 
maintained a complete response for over six years.
Figure 2.　Brain MRI at initial presentation showed a left cingulate tumor surrounded 
by widespread edema on T2-weighted imaging (A), diffusion-weighted imaging (B), and 
gadolinium-enhanced T1-weighted imaging (C).
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DISCUSSION
We report two patients with relapsed or refractory B-cell lym-
phoma with CNS involvement in whom a conditioning regimen 
using ivBU, cyclophosphamide, and etoposide (BUCYE) followed 
by ASCT was effective. This study was approved by the internal 
review board of Tokushima University (permission number 
3041).
Systemic chemotherapy using high-dose MTX, intrathecal 
chemotherapy, and whole-brain and / or local irradiation has been 
performed for malignant lymphoma with CNS involvement. 
However, its prognosis has not improved. In a historical lym-
phoma case series that included patients with secondary CNS 
involvement, the reported median survival was four months (1, 
2). In primary CNS lymphoma, a primary refractory disease 
whereby there is an insufficient response to initial methotrexate 
therapy, similar to our case 2, has a particularly poor prognosis, 
with a median survival of less than 2 months without additional 
treatment (3). Almost all anticancer drugs do not satisfactorily 
penetrate the blood brain barrier, and few drugs, such as MTX 
and Ara-C, which can relatively easily penetrate the CNS, have 
been approved for treating lymphoma in Japan. As a result, it is 
difficult to achieve good outcomes by ranimustine, VP-16, Ara-C, 
and melphalan, which is a commonly administered condition-
ing regimen (termed MEAM regimen) for relapsed lymphoma 
patients in Japan, because it does not penetrate the CNS. Thus, 
conditioning regimens using anticancer drugs that preferen-
tially enter the CNS for ASCT have been employed abroad. 
Thiotepa is an alkylating drug that has good CNS penetration, 
and has been reported to rapidly equilibrate in the lumbar and 
ventricular CSF in rhesus monkeys (4). Although thiotepa was 
available until 2009 in Japan, it was repurposed in 2019 for 
conditioning chemotherapy for ASCT with malignant lymphoma 
or pediatric solid cancer patients. Therefore, few alternative 
drugs for conditioning regimens of ASCT are available for adult 
malignant lymphoma patients with CNS involvement who are 
refractory / resistant to MTX and / or Ara-C.
 BU is another alkylator and its penetration of the CNS is 
nearly equal to that of blood plasma (5). It is frequently used in 
conditioning regimens for allogeneic hematopoietic cell trans-
plantation (6). There are several reports about ivBU-based con-
ditioning regimens followed by ASCT for refractory or resistant 
malignant lymphoma with CNS involvement (Table 1). We found 
nineteen reports in which both thiotepa and ivBU were admin-
istered for primary or secondary CNS involvement by lymphoma 
as conditioning chemotherapy followed by ASCT (7-24), and 
BUCYE was administered in one report (25). The overall sur-
vival was relatively satisfactory in most reports. In addition, 
treatment-related mortality was not high in most reports, al-
though the treatment-related mortality was 14.2% in one report, 
which was thought to be due to sepsis during neutropenia (7). 
We performed ASCT with a BUCYE conditioning regimen for 
two malignant lymphoma patients with CNS involvement who 
were resistant to MTX. Although we reduced the dose of VP-16 
in case 1, there were no adverse events except for neutropenia, 
grade 4 thrombocytopenia, and mucosal damage. There are few 
Figure 3.　Clinical course of case 2 
A 40-year-old woman with primary CNS lymphoma was treated using R-MTX + Ara-C chemotherapy. After three courses, she 
developed epilepsy with paralysis of the right lower limb. We administered ivBU, cyclophosphamide, and etoposide conditioning 
chemotherapy followed by ASCT. After engraftment, we performed whole-brain and local brain irradiation as consolidation therapy. 
She survived for two years and two months after ASCT.
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reports on ASCT for malignant lymphoma in Japan, but ivBU is 
widely administered for allogeneic stem cell transplantation in 
ivBU-based conditioning regimens. Therefore, ivBU-based condi-
tioning regimens for ASCT are tolerable for lymphoma patients. 
As a point of benefit of ivBU-based conditioning chemotherapy, 
primary refractory for MTX in primary CNS lymphoma has a 
particularly poor prognosis with a median survival of less than 
2 months, and salvage whole brain radiation also has a poor 
prognosis with median survival from initiation of whole brain 
radiotherapy reported to be 10.9 months (3, 26). Because case 2 
survived 26 months after ASCT, ivBU-based chemotherapy may 
have contributed to extending her survival. 
The sensitivity of lymphoma to BU is of concern. BU is used 
only for conditioning, and not as induction chemotherapy for ma-
lignant lymphoma. Therefore, we cannot confirm the sensitivity 
of BU before ASCT in clinical settings. However, many studies 
reported good survival of malignant lymphoma by ivBU-based 
conditioning followed by autologous or allogeneic transplantation 
(6, 25, 27). In addition, the IC50 of BU for Raji cell lines were 
0.9-1.2 μM, which are similar to that of melphalan in vitro (28). 
In clinical practice, we administer ivBU once per day and not 
fractionated to increase its concentration in the CSF as much as 
possible. It was previously reported that once-daily intravenous 
administration achieved a four-fold higher Cmax than four-
times-daily administration, although the AUC and t1 / 2 were 
similar (29). However, it is unknown whether once-daily admin-
istration of ivBU is more effective for malignant lymphoma with 
CNS involvement than four-times-daily administration. Thus, 
more clinical cases are warranted. 
In conclusion, a high-dose ivBU-based conditioning regimen 
with ASCT may be useful for refractory lymphoma with CNS 
involvement.
CONFLICT OF INTERESTS
The authors declare no conflicts of interest associated with 
this manuscript.
REFERENCES
1. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, 
Pfreundschuh M, Schmitz N : Incidence and risk factors 
of central nervous system recurrence in aggressive lym-
phoma--a survey of 1693 patients treated in protocols of 
the German High-Grade Non-Hodgkin’s Lymphoma Study 
Group (DSHNHL). Ann Oncol 18(1) : 149-157, 2007
Table 1.　Reported case of autologous stem cell transplantation for relapsed / refractory malignant lymphoma with central 
nervous system involvement. 
TRM: treatment-related mortality, ND : not described, OS : overall survival, BU: busulfan, CY : cyclophosphamide, 
CNS : central nervous system, PCNSL : primary central nervous system lymphoma, NHL : non-Hodgkin’s lymphoma.
200 M. Takahashi, et al.  Busulfan for lymphoma with CNS involvement
2. Zinzani PL, Magagnoli M, Frezza G, Prologo G, Gherlinzoni 
F, Bendandi M, Albertini P, Babini L, D’Alessandro R, Tura 
S : Isolated central nervous system relapse in aggressive 
non-Hodgkin’s lymphoma : the Bologna experience. Leuk 
Lymphoma 32(5-6) : 571-576, 1999
3. Graham MS, DeAngelis LM : Improving outcomes in pri-
mary CNS lymphoma. Best practice & research Clinical 
haematology 31(3) : 262-269, 2018
4. Strong JM, Collins JM, Lester C, Poplack DG : Pharmaco-
kinetics of intraventricular and intravenous N,N’,N’’-trieth-
ylenethiophosphoramide (thiotepa) in rhesus monkeys and 
humans. Cancer Res 46(12 Pt 1) : 6101-6104, 1986
5. Hassan M, Ehrsson H, Smedmyr B, Totterman T, Wallin 
I, Oberg G, Simonsson B : Cerebrospinal fluid and plasma 
concentrations of busulfan during high-dose therapy. Bone 
Marrow Transplant 4(1) : 113-114, 1989
6. Ciurea SO, Andersson BS : Busulfan in hematopoietic 
stem cell transplantation. Biol Blood Marrow Transplant 
15(5) : 523-536, 2009
7. Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russell 
JA, Stewart DA : High-dose thiotepa, busulfan, cyclophos-
phamide and ASCT without whole-brain radiotherapy for 
poor prognosis primary CNS lymphoma. Bone Marrow 
Transplant 31(8) : 679-685, 2003
8. Montemurro M, Kiefer T, Schuler F, Al-Ali HK, Wolf HH, 
Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, 
Niederwieser D, Schwenke M, Kruger WH, Dolken G : Pri-
mary central nervous system lymphoma treated with high-
dose methotrexate, high-dose busulfan / thiotepa, autologous 
stem-cell transplantation and response-adapted whole-
brain radiotherapy : results of the multicenter Ostdeutsche 
Studiengruppe Hamato-Onkologie OSHO-53 phase II 
study. Ann Oncol 18(4) : 665-671, 2007
9. Santos EC, Sessions J, Hutcherson D, Flowers C, Langston 
A, Waller EK : Long-term outcome of Hodgkin disease 
patients following high-dose busulfan, etoposide, cyclo-
phosphamide, and autologous stem cell transplanta-
tion--a similar experience. Biol Blood Marrow Transplant 
13(6) : 746-747, 2007
10. Alimohamed N, Daly A, Owen C, Duggan P, Stewart 
DA :  Upfront thiotepa, busulfan, cyclophosphamide, and 
autologous stem cell transplantation for primary CNS 
lymphoma : a single centre experience. Leuk Lymphoma 
53(5) : 862-867, 2012
11. Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, 
Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher 
DC, Abramson JS, Armand P, Chen YB : Autologous stem 
cell transplantation with thiotepa, busulfan, and cyclo-
phosphamide (TBC) conditioning in patients with CNS in-
volvement by non-Hodgkin lymphoma. Biol Blood Marrow 
Transplant 18(1) : 76-83, 2012
12. Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah 
K, Ghesquieres H, Damaj G, Dupriez B, Vargaftig J, Gonzalez 
A, Houillier C, Taillandier L, Hoang-Xuan K, Leblond 
V : Intensive chemotherapy with thiotepa, busulfan and 
cyclophosphamide and hematopoietic stem cell rescue in 
relapsed or refractory primary central nervous system lym-
phoma and intraocular lymphoma: a retrospective study of 
79 cases. Haematologica 97(11) : 1751-1756, 2012
13. Kiefer T, Hirt C, Spath C, Schuler F, Al-Ali HK, Wolf HH, 
Herbst R, Maschmeyer G, Helke K, Kessler C, Niederwieser 
D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, 
Montemurro M, Kruger WH, Dolken G : Long-term fol-
low-up of high-dose chemotherapy with autologous stem-
cell transplantation and response-adapted whole-brain 
radiotherapy for newly diagnosed primary CNS lymphoma: 
results of the multicenter Ostdeutsche Studiengruppe Ham-
atologie und Onkologie OSHO-53 phase II study. Ann Oncol 
23(7) : 1809-1812, 2012
14. Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH, Pyo 
DH, Hoon Lim D, Kim SJ, Kim WS : Treatment outcome of 
relapsed / refractory primary central nervous system diffuse 
large B-cell lymphoma : a single-center experience of autol-
ogous stem cell transplantation. Int J Hematol 98(3) : 346-
354, 2013
15. Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver 
SA, Moskowitz CH, Omuro AM : Autologous stem cell 
transplant in recurrent or refractory primary or secondary 
central nervous system lymphoma using thiotepa, busulfan 
and cyclophosphamide. Leuk Lymphoma 56(2) : 361-367, 
2015
16. Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones 
S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, 
Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce 
AS, McAfee SL, Spitzer TR, Nayak L, Armand P : Phase 
2 trial of high-dose rituximab with high-dose cytarabine 
mobilization therapy and high-dose thiotepa, busulfan, and 
cyclophosphamide autologous stem cell transplantation 
in patients with central nervous system involvement by 
non-Hodgkin lymphoma. Cancer 121(2) : 226-233, 2015
17. Lee MY, Kim HS, Lee JY, Lim SH, Kang ES, Ko YH, Kim 
SJ, Kim WS : Efficacy and feasibility of autologous stem cell 
transplantation in patients with diffuse large Bcell lympho-
ma with secondary central nervous system involvement. Int 
J Hematol 102(6) : 678-688, 2015
18. Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, 
Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova 
E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey 
LE, Sauter CS : R-MPV followed by high-dose chemothera-
py with TBC and autologous stem-cell transplant for newly 
diagnosed primary CNS lymphoma. Blood 125(9) : 1403-
1410, 2015
19. Oh DH, Chua N, Street L, Stewart DA : Treatment of pa-
tients with secondary central nervous system lymphoma 
with high-dose busulfan / thiotepa-based conditioning and 
autologous stem cell transplant. Leuk Lymphoma 57(1) : 28-
33, 2016
20. Qualls D, Sullivan A, Li S, Brunner AM, Collier K, Hochberg 
E, Armand P, Batchelor TT, Chen YB, DeFilipp Z : High-
dose Thiotepa, Busulfan, Cyclophosphamide, and Autolo-
gous Stem Cell Transplantation as Upfront Consolidation 
for Systemic Non-Hodgkin Lymphoma With Synchronous 
Central Nervous System Involvement. Clinical lymphoma, 
myeloma & leukemia 17(12) : 884-888, 2017
21. Doorduijn JK, van Imhoff GW, van der Holt B, Schouten 
HC, Schaafsma MR, MacKenzie MA, Baars JW, Kersten 
MJ, Lugtenburg PJ, van den Bent MJ, Enting RH, Spoelstra 
FM, Poortmans P, Bromberg JEC : Treatment of secondary 
central nervous system lymphoma with intrathecal ritux-
imab, high-dose methotrexate, and R-DHAP followed by 
autologous stem cell transplantation : results of the HOVON 
80 phase 2 study. Hematol Oncol 35(4) : 497-503, 2017
22. Scordo M, Morjaria SM, Littmann ER, Bhatia A, Chung 
HH, Maloy M, DeAngelis LM, Giralt SA, Taur Y, Sauter 
CS : Distinctive Infectious Complications in Patients with 
Central Nervous System Lymphoma Undergoing Thiotepa, 
Busulfan, and Cyclophosphamide-conditioned Autologous 
Stem Cell Transplantation. Biol Blood Marrow Transplant 
24(9) : 1914-1919, 2018
23. DeFilipp Z, Li S, El-Jawahri A, Armand P, Nayak L, Wang 
N, Batchelor TT, Chen YB : High-dose chemotherapy with 
thiotepa, busulfan, and cyclophosphamide and autologous 
201The Journal of Medical Investigation   Vol. 68  February  2021
stem cell transplantation for patients with primary central 
nervous system lymphoma in first complete remission. Cancer 
123(16) : 3073-3079, 2017
24. Hyung J, Hong JY, Yoon DH, Kim S, Park JS, Park CS, Lee 
SW, Kim JH, Ryu JS, Huh J, Suh C : Thiotepa, busulfan, 
and cyclophosphamide or busulfan, cyclophosphamide, and 
etoposide high-dose chemotherapy followed by autologous 
stem cell transplantation for consolidation of primary cen-
tral nervous system lymphoma. Ann Hematol 98(7) : 1657-
1664, 2019
25. Yoon DH, Lee DH, Choi DR, Sohn BS, Kim S, Kim SW, 
Lee JS, Lee SW, Huh J, Suh C : Feasibility of BU, CY and 
etoposide (BUCYE), and auto-SCT in patients with newly 
diagnosed primary CNS lymphoma : a single-center experi-
ence. Bone Marrow Transplant 46(1) : 105-109, 2011
26. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg 
FH, Batchelor TT, Loeffler JS : Results of whole-brain 
radiation as salvage of methotrexate failure for immuno-
competent patients with primary CNS lymphoma. J Clin 
Oncol 23(7) : 1507-1513, 2005
27. Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, Kim 
JS, Yhim HY, Chung JS : Busulfan-containing conditioning 
regimens are optimal preparative regimens for autologous 
stem cell transplant in patients with diffuse large B-cell 
lymphoma. Leuk Lymphoma 55(11) : 2490-2496, 2014
28. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky 
A, Frei E, 3rd : Alkylating agents : in vitro studies of 
cross-resistance patterns in human cell lines. Cancer Res 
46(9) : 4379-4383, 1986
29. Ryu SG, Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, Hur EH, 
Lee SH, Bae KS, Noh GJ, Lee MS, Yun SC, Han SB, Lee 
KH : Randomized comparison of four-times-daily versus 
once-daily intravenous busulfan in conditioning therapy 
for hematopoietic cell transplantation. Biol Blood Marrow 
Transplant 13(9) : 1095-1105, 2007
